Nykredit A S Takes Position in United Therapeutics Corporation $UTHR

Key Points

• Nykredit A/S initiated a position in United Therapeutics during the second quarter, purchasing 14,350 shares valued at approximately $7.8 million. Institutional investors and hedge funds collectively own 94.08% of the company.
• CEO Martine Rothblatt sold 9,500 shares for about $5.2 million, reducing her holdings by 19%; insiders have sold roughly $185.2 million worth of shares over the past 90 days.
• United Therapeutics exceeded quarterly EPS expectations with $7.27 versus the $6.86 consensus, though revenue fell 1.9% year over year to $783.3 million. Analysts maintain a “Moderate Buy” consensus with an average price target of $646.

Nykredit A S purchased a new position in shares of United Therapeutics Corporation (NASDAQ:UTHR - Free Report) in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 14,350 shares of the biotechnology company's stock, valued at approximately $7,775,000.

A number of other hedge funds have also modified their holdings of the company. Arjuna Capital boosted its holdings in shares of United Therapeutics by 2.8% in the first quarter. Arjuna Capital now owns 662 shares of the biotechnology company's stock valued at $393,000 after buying an additional 18 shares during the period. Sage Rhino Capital LLC grew its holdings in shares of United Therapeutics by 5.1% in the 1st quarter. Sage Rhino Capital LLC now owns 474 shares of the biotechnology company's stock valued at $281,000 after acquiring an additional 23 shares in the last quarter. Bryn Mawr Trust Advisors LLC boosted its holdings in shares of United Therapeutics by 5.4% in the 1st quarter. Bryn Mawr Trust Advisors LLC now owns 465 shares of the biotechnology company's stock valued at $276,000 after buying an additional 24 shares during the last quarter. Meeder Advisory Services Inc. increased its stake in shares of United Therapeutics by 4.1% during the 1st quarter. Meeder Advisory Services Inc. now owns 661 shares of the biotechnology company's stock worth $392,000 after purchasing an additional 26 shares during the last quarter. Finally, Kera Capital Partners Inc. boosted its stake in shares of United Therapeutics by 6.1% during the 1st quarter. Kera Capital Partners Inc. now owns 471 shares of the biotechnology company's stock worth $279,000 after acquiring an additional 27 shares during the period. 94.08% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at United Therapeutics

In other news, CEO Martine Rothblatt sold 9,500 shares of the stock in a transaction dated Monday, June 29th. The shares were sold at an average price of $545.80, for a total transaction of $5,185,100.00. Following the transaction, the chief executive officer owned 40,513 shares of the company's stock, valued at $22,111,995.40. This represents a 19.00% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Insiders have sold 355,553 shares of company stock worth $185,195,396 over the last 90 days. 8.60% of the stock is owned by corporate insiders.

United Therapeutics Price Performance

NASDAQ:UTHR opened at $493.10 on Tuesday. The company has a market cap of $21.15 billion, a PE ratio of 17.64, a P/E/G ratio of 2.48 and a beta of 0.56. United Therapeutics Corporation has a one year low of $409.07 and a one year high of $609.35. The firm's 50 day simple moving average is $514.63 and its 200 day simple moving average is $540.46.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last posted its quarterly earnings data on Wednesday, August 5th. The biotechnology company reported $7.27 EPS for the quarter, topping analysts' consensus estimates of $6.86 by $0.41. United Therapeutics had a return on equity of 20.18% and a net margin of 41.56%.The company had revenue of $783.30 million for the quarter, compared to analyst estimates of $804.65 million. During the same period in the previous year, the firm earned $6.41 earnings per share. The firm's quarterly revenue was down 1.9% on a year-over-year basis. Equities research analysts expect that United Therapeutics Corporation will post 26.21 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on the stock. Weiss Ratings lowered shares of United Therapeutics from a "buy (b)" rating to a "buy (b-)" rating in a research note on Thursday, August 27th. Bank of America dropped their price objective on shares of United Therapeutics from $620.00 to $613.00 and set a "neutral" rating for the company in a research note on Friday, July 10th. Morgan Stanley set a $515.00 target price on shares of United Therapeutics in a research report on Thursday, August 6th. Royal Bank Of Canada lowered their target price on shares of United Therapeutics from $704.00 to $677.00 and set an "outperform" rating on the stock in a report on Thursday, August 6th. Finally, JPMorgan Chase & Co. increased their target price on United Therapeutics from $685.00 to $687.00 and gave the stock an "overweight" rating in a report on Thursday, July 23rd. Eleven research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $646.00.

About United Therapeutics

United Therapeutics Corporation is a biotechnology company focused on developing and commercializing therapies for serious and life-threatening conditions, with a primary emphasis on pulmonary arterial hypertension (PAH). The company's products are designed to improve pulmonary blood flow and reduce the effects of this progressive disease.

United Therapeutics' PAH portfolio includes Remodulin (treprostinil) injection, Orenitram (treprostinil) extended-release tablets, and Tyvaso (treprostinil), which is available as an inhalation solution and as the Tyvaso DPI dry-powder inhaler.

Want to see what other hedge funds are holding UTHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for United Therapeutics Corporation (NASDAQ:UTHR - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.